Breaking Finance News

Zacks Investment Research downgraded Luminex Corporation (NASDAQ:LMNX) to Hold in a report released today.

Yesterday Luminex Corporation (NASDAQ:LMNX) traded 1.92% higher at $20.75. The company’s 50-day moving average is $20.93 and its 200-day moving average is $21.17. The last closing price is down -2.03% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time period. 134,429 shares of the stock traded hands, down from an average trading volume of 200,625

Zacks Investment Research has downgraded Luminex Corporation (NASDAQ:LMNX) to Hold in a report released on 11/29/2016.

Previously on Tuesday November 03, 2015, Leerink Swann reported on Luminex Corporation (NASDAQ:LMNX) increased the target price from $18.00 to $21.00. At the time, this indicated a possible downside of -0.04%.

See Chart Below

Luminex Corporation (NASDAQ:LMNX)

Luminex Corporation has a 52 week low of $17.29 and a 52 week high of $23.75 with a P/E ratio of 23.92 The company’s market cap is currently $0.

General Information About Luminex Corporation (NASDAQ:LMNX)

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company's FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to various types of testing laboratories. The Company's assay products are focused on three segments of the molecular diagnostic testing market: human genetics, personalized medicine and infectious disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.